Eli Lilly 2012 Annual Report Download - page 141

37
Executive Compensation
Summary Compensation Table
Name and
Principal Position Year Salary ($) Bonus ($)
Stock
Awards
($) 3
Option
Awards
($)
Non-Equity
Incentive Plan
Compensation
($) 4
Change
in Pension
Value
($) 5
All Other
Compensation
($) 6
Total
Compensation
($)
John C. Lechleiter, Ph.D. 12012 $1,500,000 $0 $5,625,000 $0 $2,982,000 $4,423,633 $90,000 $14,620,633
Chairman, President, and
Chief Executive Officer 2011 $1,500,000 $0 $5,625,000 $0 $2,625,000 $6,530,094 $90,000 $16,370,094
2010 $1,500,000 $0 $8,175,000 $0 $2,982,000 $3,757,545 $90,000 $16,504,545
Derica W. Rice 2012 $990,000 $0 $2,850,000 $0 $1,265,220 $1,770,767 $59,400 $6,935,387
Executive Vice President,
Global Services and
Chief Financial Officer
2011 $984,167 $0 $2,850,000 $0 $1,107,188 $940,589 $59,050 $5,940,993
2010 $955,000 $0 $3,270,000 $0 $1,220,490 $996,723 $57,300 $6,499,513
Jan M. Lundberg, Ph.D. 2012 $978,500 $0 $2,250,000 $0 $1,250,523 $307,275 $58,710 $4,845,008
Executive Vice President,
Science and Technology
and President, Lilly
Research Laboratories
2011 $973,750 $0 $2,062,500 $0 $1,095,469 $232,128 $58,425 $4,422,272
2010 $946,401 $1,000,000 2$6,225,000 2$0 $1,209,501 $83,150 $87,833 $9,551,885
Robert A. Armitage 2012 $840,900 $0 $1,500,000 $0 $955,262 $629,012 $50,454 $3,975,628
Senior Vice President and
General Counsel 2011 $840,900 $0 $1,500,000 $0 $840,900 $595,293 $50,454 $3,827,547
2010 $836,817 $0 $2,180,000 $0 $950,624 $521,237 $50,209 $4,538,886
Enrique A. Conterno 2012 $669,500 $0 $1,500,000 $0 $713,018 $992,187 $40,170 $3,914,875
Senior Vice President and
President, Lilly Diabetes 2011 $666,250 $0 $1,500,000 $0 $624,609 $887,380 $39,975 $3,718,214
2010 $650,000 $0 $1,962,000 $0 $692,250 $275,998 $39,000 $3,619,248
1 Supplement to the "Summary Compensation Table." The PA grant values included in the "Stock Awards" column
are based on the probable payout outcome anticipated at the time of grant, which was different from the target
value in each year. For purposes of comparison, the supplemental table below shows Dr. Lechleiter's target
compensation, which has remained the same for the past three years as the company entered the current period
of patent expirations.
Name Year Annualized Salary Target Stock Awards Target Cash Incentive Bonus Total
John C. Lechleiter, Ph.D. 2012 $1,500,000 $7,500,000 $2,100,000 $11,100,000
2011 $1,500,000 $7,500,000 $2,100,000 $11,100,000
2010 $1,500,000 $7,500,000 $2,100,000 $11,100,000
2 Dr. Lundberg received a signing bonus and a one-time RSU award upon joining the company in January 2010.
3 This column shows the grant date fair value of PAs and SVAs computed in accordance with FASB ASC Topic 718.
Values for awards subject to performance conditions (PAs) are computed based upon the probable outcome of the
performance condition as of the grant date. A discussion of assumptions used in calculating award values may be
found in Note 9 to our 2012 audited financial statements in our Form 10-K.
The table below shows the minimum, target, and maximum payouts for the 2012-2013 PA grant included in this
column of the Summary Compensation Table.
Name Payout Date Minimum Payout Target Payout Maximum Payout
Dr. Lechleiter January 2014 $0 $3,750,000 $5,625,000
Mr. Rice January 2014 $0 $1,900,000 $2,850,000
Dr. Lundberg January 2014 $0 $1,500,000 $2,250,000
Mr. Armitage January 2014 $0 $1,000,000 $1,500,000
Mr. Conterno January 2014 $0 $1,000,000 $1,500,000
4 Payments for 2012 performance were made in March 2013 under the bonus plan. All bonuses paid to named
executive officers were part of a non-equity incentive plan.
5 The amounts in this column are the change in pension value for each individual, calculated by our actuary. No
named executive officer received preferential or above-market earnings on deferred compensation.
6 The table below shows the components of the “All Other Compensation” column for 2010 through 2012, which